모더나 이어 화이자도 "코로나 백신 95% 면역효과"…최종 결과<br /><br />Some good news, a week after Pfizer and BioNTech revealed their final stage vaccine trial was over 90-percent effective against COVID-19,... their final analysis is showing even better numbers: 95-percent.<br />With no serious safety concerns reported,... the vaccine could be rolled out before Christmas.<br />Lee Seung-jae reports.<br />Pfizer and its Germany partner BioNTech could get their vaccine candidate approved for emergency authorization in the U.S. and Europe next month,... after its final trial results showed it had a 95-percent success rate without any serious side effects.<br />According to the drugmakers Wednesday,... the efficacy was found to be consistent throughout different age groups and ethnicities.<br />This includes those in the high-risk age group of 65 and older.<br />Among the over 43-thousand people in the final stage of the trial,... 170 contracted COVID-19,... with 162 of them given only a placebo shot.<br />Out of the 10 people who reported severe COVID-19 symptoms,... only one had received the vaccine.<br />The final analysis also showed it had a 94-percent efficacy rate among those over 65 years.<br />Armed with the results,... Pfizer says it will seek U.S. FDA emergency use authorization "within days".<br />The CEO of BioNTech says this means the vaccine could begin distribution to the U.S. and Europe next month.<br />"If everything goes well we could start to supply the vaccines to Europe and the United States in the second half of December and you can see that of course as a Christmas present but it is of course, of course, of course, most important, to answer all the questions and to get the approval first."<br />According to the drugmakers,... they'll produce 50 million doses in 2020,... and up to 1-point-3 billion next year.<br />Lee Seung-jae, Arirang News.<br />
